
FDA Clears Phase 1 Trial of MRANK-106 in Advanced Solid Tumors
The FDA has cleared the investigational new drug (IND) application for MRANK-106, a first-in-class dual WEE1/YES1 kinase inhibitor for advanced solid tumors. Preclinical data show superior efficacy, reduced hematotoxicity, and broad activity in …